Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Target Lowered at Royal Bank Of Canada

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target dropped by equities researchers at Royal Bank Of Canada to $1.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price target would suggest a potential upside of 143.90% from the company’s previous close.

EYPT has been the topic of a number of other research reports. Citigroup lowered their price objective on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating on the stock in a report on Tuesday, August 18th. Weiss Ratings upgraded Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 1st. Mizuho reissued a “neutral” rating and set a $0.50 target price on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Cantor Fitzgerald cut Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Monday, August 17th. Finally, Guggenheim cut Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday. Two analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $21.85.

Eyepoint Pharmaceuticals Price Performance

Shares of EYPT stock traded down $0.03 during mid-day trading on Tuesday, hitting $0.41. The stock had a trading volume of 41,632,898 shares, compared to its average volume of 3,228,910. The firm has a market cap of $35.35 million, a PE ratio of -0.11 and a beta of 1.67. The company’s 50-day simple moving average is $4.77 and its 200-day simple moving average is $10.30. Eyepoint Pharmaceuticals has a fifty-two week low of $0.40 and a fifty-two week high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The firm had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. On average, analysts expect that Eyepoint Pharmaceuticals will post -3.51 EPS for the current year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. California State Teachers Retirement System boosted its holdings in Eyepoint Pharmaceuticals by 2,158.3% during the first quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock worth $1,355,000 after buying an additional 100,447 shares in the last quarter. Commodore Capital LP purchased a new position in Eyepoint Pharmaceuticals in the first quarter valued at about $36,414,000. Walleye Capital LLC purchased a new position in Eyepoint Pharmaceuticals in the first quarter valued at about $3,869,000. Swiss National Bank purchased a new position in Eyepoint Pharmaceuticals in the first quarter valued at about $1,900,000. Finally, Stempoint Capital LP lifted its position in shares of Eyepoint Pharmaceuticals by 129.1% during the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock valued at $10,451,000 after acquiring an additional 456,915 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Key Stories Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Royal Bank of Canada said the upcoming diabetic macular edema (DME) study readout could provide a potential catalyst, particularly as EyePoint shifts resources toward its late-stage DME program. EyePoint’s DME Study Readout a Catalyst After wAMD Trial Misses Endpoint, RBC Says
• Positive Sentiment: RBC reduced its price target to $1.00 but maintained a “sector perform” rating, implying substantial potential upside if the DME program produces favorable results. Jefferies also set a $1.00 target after moving to “hold.” RBC price target update
• Neutral Sentiment: Laidlaw reaffirmed its “hold” rating, while HC Wainwright and Mizuho maintained “neutral” ratings. Mizuho’s new $0.50 target indicates only modest upside, reflecting continued uncertainty.
• Neutral Sentiment: Unusual options activity included purchases of 7,885 call contracts, about 69% above typical volume. This may signal speculative interest but does not change the company’s fundamental outlook.
• Negative Sentiment: EyePoint is cutting 53% of its workforce and halting wet-AMD clinical trials early after the disappointing LUCIA results, concentrating spending on DME and reducing operating costs. EyePoint Announces Strategic Prioritization
• Negative Sentiment: Guggenheim downgraded EYPT to “neutral,” Jefferies moved to “hold,” and JPMorgan reaffirmed an “underweight” rating, highlighting reduced confidence in the company’s pipeline.
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations related to the trial disclosure and subsequent shareholder losses, adding legal and reputational risk. EyePoint Pharmaceuticals Investigation Notice

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.